» Articles » PMID: 35799614

Multimorbidity Patterns and Risk of Hospitalisation in Children: A Population Cohort Study of 3.6 Million Children in England, with Illustrative Examples from Childhood Cancer Survivors

Overview
Specialty Health Services
Date 2022 Jul 8
PMID 35799614
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Population-level estimates of hospitalisation risk in children are currently limited. The study aims to characterise morbidity patterns in all children, focusing on childhood cancer survivors versus children without cancer.

Methods: Employing hospital records of children aged <19 years between 1997 to 2018 in England, we characterised morbidity patterns in childhood cancer survivors compared with children without cancer. The follow-up began on the 5 anniversary of the index hospitalisation and the primary outcome was the incidence of comorbidities.

Findings: We identified 3,559,439 eligible participants having 12,740,666 hospital admissions, with a mean age at study entry of 11.2 years. We identified 32,221 patients who survived for at least 5 years since their initial cancer diagnosis. During the follow-up period and within the whole population of 3.6 million children, the leading conditions for admission were (i) metabolic, endocrine, digestive renal and genitourinary conditions (84,749, 2.5%), (ii) neurological (35,833, 1.0%) and (iii) musculoskeletal or skin conditions (23,574, 0.7%), fever, acute respiratory and sepsis (22,604, 0.7%). Stratified analyses revealed that females and children from socioeconomically deprived areas had a higher cumulative incidence for morbidities requiring hospitalisation ( < 0.001). At baseline (5 years after the initial cancer diagnosis or initial hospitalisation for survivors and population comparisons, respectively), cancer survivors experienced a higher prevalence of individual conditions and multimorbidity (≥ 2 morbidities) compared with children without cancer. Cox regression analyses showed that survivors had at least a 4-fold increase in the risk of hospitalisation for conditions such as chronic eye conditions (hazard ration (HR):4.0, 95% confidence interval (CI): 3.5-4.7), fever requiring hospitalisation (HR: 4.4, 95% CI: 3.8-5.0), subsequent neoplasms (HR: 5.7, 95% CI:5.0-6.5), immunological disorders (HR: 6.5, 95% CI:4.5-9.3) and metabolic conditions (HR: 7.1, 95% CI:5.9-8.5).

Interpretation: The overall morbidity burden among children was low in general; however, childhood cancer survivors experienced a higher prevalence and subsequent risk of hospitalisation for a range of morbidities. Targeted policies may be required to promote awareness on health vulnerabilities and gender disparity and to improve advocacy for healthcare in deprived communities.

Funding: Wellcome Trust, National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre and Academy of Medical Sciences. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Citing Articles

Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records.

Zelt S, Cooney T, Yu S, Daral S, Krebs B, Markan R Neurooncol Pract. 2024; 11(5):583-592.

PMID: 39279771 PMC: 11398936. DOI: 10.1093/nop/npae037.


Access to primary care for children and young people (CYP) in the UK: a scoping review of CYP's, caregivers' and healthcare professionals' views and experiences of facilitators and barriers.

Herlitz L, Ashford E, Powell C, Herbert K, Morris S, Woodman J BMJ Open. 2024; 14(5):e081620.

PMID: 38816045 PMC: 11141190. DOI: 10.1136/bmjopen-2023-081620.


Dental management of long-term childhood cancer survivors: a systematic review.

Seremidi K, Gizani S, Dahllof G, Barr-Agholme M, Kloukos D, Tsilingaridis G Eur Arch Paediatr Dent. 2024; 25(5):611-636.

PMID: 38773051 PMC: 11442565. DOI: 10.1007/s40368-024-00896-5.


Healthcare costs of cancer among children, adolescents, and young adults: A scoping review.

Nabukalu D, Gordon L, Lowe J, Merollini K Cancer Med. 2024; 13(3):e6925.

PMID: 38214042 PMC: 10905233. DOI: 10.1002/cam4.6925.


Pan-cancer analyses of the associations between 109 pre-existing conditions and cancer treatment patterns across 19 adult cancers.

Chang W, Lai A Sci Rep. 2024; 14(1):464.

PMID: 38172343 PMC: 10764847. DOI: 10.1038/s41598-024-51161-0.


References
1.
Armstrong G, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson M . Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014; 32(12):1218-27. PMC: 3986385. DOI: 10.1200/JCO.2013.51.1055. View

2.
de Fine Licht S, Rugbjerg K, Gudmundsdottir T, Bonnesen T, Asdahl P, Holmqvist A . Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors. PLoS Med. 2017; 14(5):e1002296. PMC: 5423554. DOI: 10.1371/journal.pmed.1002296. View

3.
Bhakta N, Liu Q, Ness K, Baassiri M, Eissa H, Yeo F . The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112):2569-2582. PMC: 5798235. DOI: 10.1016/S0140-6736(17)31610-0. View

4.
Smith L, Glaser A, Greenwood D, Feltbower R . Cumulative burden of subsequent neoplasms, cardiovascular and respiratory morbidity in young people surviving cancer. Cancer Epidemiol. 2020; 66:101711. DOI: 10.1016/j.canep.2020.101711. View

5.
Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View